Advertisement

The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff.
Please visit the COVID-19 & Cancer Resource Center where COVID-related content is freely available.

 

We welcome pre-submission inquiries! Simply email the editors at cancerimmunolres@aacr.org. Learn more.

From the Current Issue

  • Research Articles
    Myeloma-Secreted Galectin-1 Potently Interacts with CD304 on Monocytic Myeloid-Derived Suppressor Cells
    Ji-Young Lim, Tae-Woo Kim, Da-Bin Ryu, Sung-Soo Park, Sung-Eun Lee, Byung-Soo Kim and Chang-Ki Min
    Cancer Immunol Res May 1 2021 9 (5) 503-513; DOI:10.1158/2326-6066.CIR-20-0663

    Multiple myeloma cell–derived galectin-1 is shown to interact with CD304 on monocytic myeloid-derived suppressor cells, inducing their migration and inhibiting the cytotoxic activity of melphalan, suggesting the interaction as a potential therapeutic target for multiple myeloma.

  • Research Articles
    Oncogenic KIT Modulates Type I IFN–Mediated Antitumor Immunity in GIST
    Mengyuan Liu, Mark S. Etherington, Andrew Hanna, Benjamin D. Medina, Gerardo A. Vitiello, Timothy G. Bowler, Nesteene J. Param, Lillian Levin, Ferdinand Rossi and Ronald P. DeMatteo
    Cancer Immunol Res May 1 2021 9 (5) 542-553; DOI:10.1158/2326-6066.CIR-20-0692

    Inhibition of oncogenic KIT in gastrointestinal stromal tumors decreases type I IFN signaling, impairing antigen presentation and diminishing CD8+ T-cell antitumor responses. The data suggest enhancing type I IFN signaling may counter the negative immune effects of imatinib.

OnlineFirst Articles

Load more

Trending - Altmetric

No Altmetric data available.
Advertisement

Back to top